Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem
26.3.2026 15:00:00 EET | Business Wire | Press release
Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms.
Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap widens, confidence erodes and competitive advantage is lost. Orchestrated Planning removes decision latency by harmonizing data, people, processes and agentic capabilities to help organizations move at the speed of the market.
Vena provides a governed, finance-orchestrated planning engine designed from the ground up to unlock the full power of Microsoft Excel and harness its increasing accessibility and reach through emerging LLM tools such as Microsoft Copilot and Claude. The Vena Platform and Vena AI agents help finance teams accelerate planning, analysis and execution with AI-driven decision-making in their natural flow of work within the tool they know and love.
Acterys extends Vena’s offerings into advanced operational planning and application development through proprietary Power BI write-back and multidimensional modeling aligned with Microsoft Fabric. This enables IT and Finance teams to build quickly and securely within a trusted, governed environment that empowers organizations to plan and run better within Power BI and Fabric.
The better-together power of the two platforms will be unlocked immediately with data and process integration, enabling customers to deploy Orchestrated Planning across Finance, IT and their business stakeholders. Acterys CEO Mike Zack will continue to lead Acterys as General Manager, focused on scaling enterprise operational planning. Acterys Chief Technology Officer Hesam Ziaei joins Vena as VP, R&D, partnering on a unified roadmap with agentic functionality embedded across the platforms.
“Closing this acquisition expands how our customers can orchestrate data, people and agents to plan better and achieve more,” said Hunter Madeley, CEO of Vena. “With Acterys, we’re extending our reach deeper into the Microsoft ecosystem to help organizations turn decisions into on-time execution with confidence.”
“Acterys brings operational planning and execution directly into Power BI and Fabric,” said Mike Zack, General Manager, Acterys. “Together with Vena, we extend planning beyond finance—connecting decisions in Excel to governed execution in Power BI so organizations can act with greater control and clarity.”
Both Vena and Acterys remain available via the Microsoft Marketplace.
About Vena
Vena is a Microsoft-native Orchestrated Performance Management platform that enables financial and operational planning, consolidation and close, analytics and execution across Microsoft Excel, Power BI, Azure and Fabric. With a governed, AI-ready data foundation and agentic AI embedded in planning workflows, Vena helps organizations make better decisions and execute on time with confidence. Thousands of organizations worldwide rely on Vena to perform better and achieve more. For more information, visit venasolutions.com.
About Acterys
Acterys provides enterprise-grade planning, analytics and application development solutions for Microsoft Power BI, Azure and Fabric. Its modular, scalable platform empowers organizations to build connected, data-driven applications at scale. Visit Acterys.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260326599107/en/
Contacts
Jonathan Paul
Vice President, Content Marketing
Jpaul@venacorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CSG Named a Leader in the Gartner® Magic Quadrant™ for Customer Journey Analytics & Orchestration26.3.2026 17:30:00 EET | Press release
Rising customer expectations for connected, relevant, and effortless interactions are making journey analytics and orchestration critical to delivering consistent, personalized experiences that earn loyalty. As CSG® (NASDAQ: CSGS) helps businesses to meet and exceed those expectations, the company today announced that CSG has been named a Leader in the 2026 Gartner® Magic Quadrant™ for Customer Journey Analytics & Orchestration. The evaluation assessed the company’s overall Completeness of Vision and Ability to Execute. “It’s not enough to understand the customer – businesses must act on that knowledge in real time and prove the value of every customer interaction,” said Katie Costanzo, President, Customer Experience, CSG. “That requires a unified system that turns real-time data into clear decisions, measurable outcomes, and experiences customers can trust. I am incredibly proud that CSG has been named a Leader in the inaugural Gartner Magic Quadrant for Journey Analytics & Orchestrat
India: The Up-and-Coming Solar Market26.3.2026 17:27:00 EET | Press release
Solar energy expansion is booming worldwide. India, in particular, is seeing rapid growth thanks to state funding programs, tax incentives, subsidies and green loans from banks. In 2025, 37.5 gigawatts were added – a 50 percent increase from the previous year. The 2026 budget provides for a deployment of 45 to 50 gigawatts, allowing the most densely populated country to become the second largest solar market in the world. Intersolar Europe will shine a spotlight on the south Asian country from June 23–25 in Munich. India is an up-and-coming market for the international PV industry. There will be numerous events where visitors can learn about the market, new business opportunities and the structure of new supply chains. The exhibition will take place as part of The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry. More than 100,000 visitors and 2,800 exhibitors from all over the world are expected to attend. This press release features multimedia. View
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 15:00:00 EET | Press release
Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.1 CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results. The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% s
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 14:30:00 EET | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the European Union, was designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496—the first-ever GPX4 (selective glutathione peroxidase 4) modulator to be studied in human trials, and the first specifically targeting cellular rejuvenation, an area of great interest to the scientific community as a new therapeutic pathway. The study met its primary endpoint, with RLS-1496 also demonstrating early signs of efficacy. Preliminary Trial Results RLS-1496 was well-tolerated,
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 14:30:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by the expanding use of highly effective antitumor therapies - including chemotherapy, radiotherapy and targeted therapies - many of which are associated with cardiovascular toxicities. Global studiesi show that heart-related complications are now the second leading cause of death in cancer survivors, after the cancer itself, accounting for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom